Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 13:30 save search
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Published: 2024-03-27 (Crawled : 13:30) - globenewswire.com
AVTE M | $21.86 1.2% 1.19% 220K
|
Professional, Scientific, and T...
|
| O: 6.78%
H: 7.19%
C: 4.05%
conference international trial therapeutics
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Published: 2024-03-20 (Crawled : 13:30) - globenewswire.com
IMMX | $2.21 0.0% 64K
|
|
| O: -2.9%
H: 10.07%
C: 2.24%
nxc-201 cancer biopharma trial
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
Published: 2024-03-15 (Crawled : 13:30) - biospace.com/
LTRN | $5.42 -6.07% -6.46% 240K
|
Health Technology
|
| O: 2.04%
H: 18.0%
C: 16.0%
lp-284 pharma trial
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Published: 2024-03-07 (Crawled : 13:30) - globenewswire.com
IKT | $2.1 0.19% 52K
|
Health Technology
|
| O: 0.41%
H: 2.89%
C: 0.0%
conference alzheimer’s update international disorders neurological parkinson’s trial therapeutics
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-03-04 (Crawled : 13:30) - prnewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: -1.85%
H: 27.88%
C: 20.93%
nrx-101 depression treatment pharmaceuticals trial
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
Published: 2024-03-01 (Crawled : 13:30) - biospace.com/
KRBP | $2.5 -90.21% 830
|
Health Technology
|
| O: -4.03%
H: 0.0%
C: -5.6%
biopharma ongoing trial
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
SPRC | $1.235 -4.26% -4.45% 150K
|
Manufacturing
|
| O: -1.07%
H: 8.11%
C: 3.24%
treatment enabling trial
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
Published: 2024-02-27 (Crawled : 13:30) - globenewswire.com
IMNN | $1.16 3.11% 3.02% 95K
|
Manufacturing
|
| O: 4.08%
H: 13.39%
C: 11.81%
imnn-001 cancer trial advanced
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
Published: 2024-02-21 (Crawled : 13:30) - neurosense.investorroom.com
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: -3.65%
H: 0.0%
C: -5.3%
als positive trial results
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
Published: 2024-02-15 (Crawled : 13:30) - biospace.com/
RPTX 4 | $3.14 3.97% 3.82% 220K
|
Health Technology
|
| O: 2.79%
H: 4.14%
C: -0.71%
rp-1664 first trial therapeutics
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
Published: 2024-02-14 (Crawled : 13:30) - biospace.com/
KRBP | $2.5 -90.21% 830
|
Health Technology
|
| O: 13.51%
H: 48.81%
C: 22.02%
first indicate tumor trial results
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
Published: 2024-02-07 (Crawled : 13:30) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 1.66%
H: 4.13%
C: 4.11%
arm trial therapeutics
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
LIXT | $3.351 4.68% 11K
|
Health Technology
|
| O: 17.09%
H: 4.29%
C: -7.73%
lb-100 first cell immunotherapy trial
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
Published: 2024-01-23 (Crawled : 13:30) - globenewswire.com
FEMY | $1.33 1.53% 1.5% 160K
|
Manufacturing
|
| O: -1.76%
H: 5.52%
C: -0.13%
trial
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
Published: 2024-01-23 (Crawled : 13:30) - biospace.com/
SRRK 4 | $13.85 -0.72% -0.72% 710K
|
Health Technology
|
| O: 1.1%
H: 1.48%
C: -5.33%
fda obesity treat clearance application trial rock
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
Published: 2024-01-17 (Crawled : 13:30) - globenewswire.com
KA A | $0.5196 6.89% 6.45% 480K
|
Manufacturing
|
| O: 11.46%
H: 0.0%
C: -13.29%
vista-101 tumors update ongoing trial advanced
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
Published: 2024-01-17 (Crawled : 13:30) - globenewswire.com
ELTX | $8.465 2.86% 2.78% 28K
|
|
| O: 1.89%
H: 0.0%
C: -5.58%
eli-002 vaccine symposium asco trial therapeutics study
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: 1.25%
H: 4.12%
C: -2.06%
trial glioblastoma
Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
Published: 2024-01-03 (Crawled : 13:30) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: 3.15%
H: 6.1%
C: -4.07%
trial
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Published: 2024-01-03 (Crawled : 13:30) - globenewswire.com
SLRX | $0.4848 -2.88% 6.2K
|
Commercial Services
|
| O: 4.67%
H: 4.4%
C: -4.66%
treat seclidemstat trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.